<DOC>
	<DOC>NCT00583921</DOC>
	<brief_summary>Single center investigator initiated sponsored by Guidant Boston Scientific Corp. to evaluate the benefit of ventricular rate regularization (VRR) in patients with congestive heart failure (CHF) and significant atrial fibrillation (AF) burden.</brief_summary>
	<brief_title>Ventricular Rate Regularization for Improved Quality of Life in Patients With CHF and AF</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Be between 1885 years old Be willing and able to give informed consent Patient currently has a CRTD or ICD with &gt; 20% atrial fibrillation burden as recorded by defibrillator follow up report or a history of atrial fibrillation prior to implant. Patient has the ability to complete a Six minute walk test with the only limiting factors to be fatigue or shortness of breath. Expected mortality less than 6 months due to noncardiac causes. Pregnant women. Creatinine greater than or equal to 2.5 mg/dl. Anemia (HCT less than 30) COPD causing significant dyspnea Orthopedic problems affecting 6 minute walk.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>ICD</keyword>
	<keyword>BiV ICD</keyword>
	<keyword>CHF</keyword>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>AF</keyword>
</DOC>